<DOC>
	<DOCNO>NCT01167530</DOCNO>
	<brief_summary>The phase 1 study evaluats RAD001 combination radiotherapy non-small cell lung cancer . First phase study : RAD001 ( everolimus ) administer per o every Monday , one week radiotherapy continue 3.5 week end radiotherapy . Chemotherapy give 4.5 week end radiotherapy . Three patient cohort plan , receive 10 , 20 50 mg RAD001 per week.Second phase study : RAD001 ( everolimus ) administer per o every day one week radiotherapy continue 3.5 week end radiotherapy . Chemotherapy give 4.5 week end radiotherapy . Three patient cohort plan , receive 2.5 , 5 10 mg RAD001 per day.The two phase study may conduct independently parallel.Radiotherapy : 66 Grays 6.5 week . ( 5 weekly fraction 2 Grays ) Chemotherapy : 2 cycle : Cisplatin 100 mg/m2 D1 , Navelbine 25 mg/m2 D1 , D8 , every 21 day .</brief_summary>
	<brief_title>Study Evaluate RAD001 Combination With Radiotherapy Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Unresectable nonsmall cell lung cancer , stage IIIA/B , stage IV primary tumor symptomatic ( cough , dyspnea , pain ) without extrathoracic lesion rapidly evolve patient receive radiotherapy curative dose 2 . Measurable lesion , document histologically , potentially accessible fiberoptic bronchoscopy . 3 . Age &gt; 18 year , WHO 01 , 4 . Neutrophil count &gt; 1500 /mm3 , Hemoglobin &gt; 9 g/dL , Platelet count &gt; 100,000/mm3 5 . Bilirubin &lt; 1.5 mg/dL , Transaminases &lt; 3 N , albumin &gt; 30 g / L , PT &gt; 70 % 6 . Creatinine &lt; 120 Î¼M/L 7 . Patient information inform consent form sign . 8 . No previous treatment lung cancer ( surgery , radiotherapy , chemotherapy ) . 1 . Patients previously treat RAD001 ( everolimus ) mTOR inhibitor 2 . Stage IV primary tumor symptomatic extrathoracic lesion rapidly evolve require systemic treatment 3 . Previous radiotherapy , 4 . Venous arterial thrombosis , pulmonary embolism previous six month 5 . Concomitant treatment phenytoin , phenobarbital antiepileptic agent , history epilepsy 6 . Concomitant treatment medicinal product inhibit , induce substrate CYP3A4 ( inhibitor : atazanavir , clarithromycin , indinavir , itraconazole , ketoconazole , nefazodone , nelfinavir , ritonavir , saquinavir , telithromycin , amprenavir , aprepitant , diltiazem , erythromycin , fluconazole , fosamprenavir , verapamil , ciclosporin , voriconazoleinducers : rifampicin , carbamazepine , rifabutinsubstrates : midazolam , buspirone , felodipine ) 7 . Concomitant therapy agent otherwise use treatment cancer ( example methotrexate rheumatoid arthritis ) . 8 . Chronic treatment corticosteroid another immunosuppressant 9 . Patients active bleeding diathesis take oral vitamin K antagonist ( except lowdose Coumadin ( warfarin sodium ) ) 10 . Other concurrent severe and/or uncontrolled disease could compromise participation study ( i.e . uncontrolled diabetes , uncontrolled hypertension , severe infection , severe malnutrition , unstable angina , congestive heart failure New York Heart Association Class III IV , ventricular arrhythmia , active ischemic heart disease , myocardial infarction previous six month , chronic liver renal disease , active upper GI tract ulceration ) 11 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( EVEROLIMUS ) ( i.e . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) 12 . HIV seropositivity 13 . Patient virological test positive hepatitis B ( HBs positive ) 14 . Patients active cutaneous , mucosal , ocular gastrointestinal disorder grade &gt; 1 15 . Previous cancer ( except basal cell skin cancer cervical carcinoma situ ) 3 year prior enter trial . 16. important pulmonary fibrosis Xray 17 . Women could become pregnant currently breastfeed ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Everolimus</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Chemotherapy</keyword>
</DOC>